#### COPY OF PAPERS ORIGINALLY FILED

W

23 c 2 PATENT 52071.00004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:  JAN 2 9 2002	) Group Art Unit: Not Yet Determined
Nestor ANNIBALI	) Examiner: Not Yet Determined
Serial No.: 09/955,259	) ) Oo.
Filed: September 12, 2001	) AIGINALLY FILES
For: EXPRESSION OF A HUMAN INSULIN PRECURSOR IN P. PASTORIS	

### TRANSMITTAL LETTER

BOX SEQ. Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated November 9, 2001, enclosed herewith for filing are the following documents:

- 1. Preliminary Amendment;
- Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- 3. Sequence Listing;

## CERTIFICATE OF MAILING (37 C.F.R. § 1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

	<i>_</i>	Vivian M. Gutierrez	
		Name of Person Mailing Paper	
nuary 9, 2002		Vuran M. Lurenez	/
ate of Deposit	<del>_</del>	Signature of Person Mailing Paper	·

- 4. 3 ½ Disk; and
- 5. Postcard.

The Commissioner is authorized to charge Squire, Sanders & Dempsey's Deposit Account No. 07-1853 for any fees required under 37 CFR §§ 1.16 and 1.17 that are not covered, in whole or in part, by a check enclosed herewith and to credit any overpayment to said Deposit Account No. 07-1853.

Respectfully submitted,

SQUIRE, SANDERS & DEMPSEY L.L.P.

Dated: January 9, 2002

Reg. No. 41,425

801 S. Figueroa Street 14<sup>th</sup> Floor Los Angeles, CA 90017-5554 (213) 689-6533

Los Angeles; Document #:68913v1



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231

www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/955,259

San Francisco, CA 94111

09/12/2001

Nestor Annibali

52071.4

**CONFIRMATION NO. 1187** 

FORMALITIES LETTER

OC000000007052302\*

Squire, Sanders & Dempscy L.L.P. Suite 300
One Maritime Plaza

Date Mailed: 11/09/2001

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE